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Subjects
Background
Decrease length of stay by 
checking methotrexate levels 
more frequently and changing 
the methotrexate level for 
discharge from <0.1µM to 
<0.2µM.
•  In patients receiving high dose methotrexate, the 
greatest concern is renal toxicity
•  The elimination half-life of high dose methotrexate 
is within the range of 8 to 15 hours
•  After IV administration, approximately 80-90% of 
the methotrexate is excreted within the urine as 
unchanged drug within 24 hours
•  The majority of patients will have a serum 
methotrexate level <0.1µM between 24 and 48 
hours 
•  There is limited data detailing a safe methotrexate 
level for hospital discharge and no data to support 
that discharge with a methotrexate level of <0.1µM 
is safer than <0.2µM
•  The cost of checking a stat serum methotrexate 
level is $64.45
•  The cost of an additional night stay in the hospital is 
significantly more expensive
•  It is cost effective to check methotrexate levels 
twice daily in an effort to decrease length of stay in 
patients receiving high dose methotrexate
•  Diagnosis included primary CNS lymphoma, peripheral T cell lymphoma, DLBCL of the testicle, T-ALL,  
B-ALL, DLBCL with double hit
•  Chemotherapy regimens received included HyperCVAD, DeAngelis protocol, and high dose methotrexate 
and rituxan
•  Ages of patients ranged from 27 to 79
Results
•  A total of 21 hospitalizations were reviewed prior to instituting the new protocol
•  The average length of stay was 4.47 days
•  In reviewing the 21 hospitalizations, 8 hospitalizations could have had reduced length of stay by at least 
1 day implementing the new protocol
•  One hospitalization could have been reduced by 2 nights if the new protocol had been implemented
•  A total of 43 hospitalizations for high dose methotrexate were reviewed using the new protocol
•  The average length of stay with the new protocol was 3 days
•  Average LOS was reduced by 1.47 nights
•  There were 7 hospitalizations where the patient was discharged with a methotrexate level >0.1µM
•  All 7 had an outpatient methotrexate level the following day, all methotrexate levels were <0.1µM
Conclusions
•  The average length of stay was decreased by 1.47 days implementing the new protocol. 
•  The new protocol is safe with regards to discharging patients with slightly higher methotrexate levels, 
all repeat methotrexate levels as an outpatient were at the goal of <0.1µM
•  The new protocol for discharging patients receiving high dose methotrexate is both safe and cost 
effective. 
•  The new protocol is now the new standard of care in patients receiving high dose methotrexate. 
Old Protocol
− 24 hours after methotrexate 
infusion is complete a 
methotrexate level is checked 
and leucovorin dose is based on 
the methotrexate level
− Methotrexate levels are then 
checked every 24 hours until 
levels are <0.1µM
− When levels are <0.1µM then the 
patient may be discharged on 
leucovorin 15mg PO every 6 
hours for a total of 24 hours
New Protocol
− 24 hours after the completion of the 
methotrexate infusion, a 
methotrexate level will be checked 
and leucovorin started
− The methotrexate level will then be 
checked twice daily, at 4:00 and 
13:00 until the level is <0.2µM
− In patients with a normal creatinine
(<1.2) and normal CrCl (>60 mL/min) 
or stable creatinine (no change 
>0.3md/dL during the hospital stay), 
once levels are  <0.2µM the patient 
is discharged to home and given a 
script to have a methotrexate level 
checked 24 hours later in the MPA to 
ensure that the level is <0.1µM 
− In patients with a level <0.2µM and 
abnormal or unstable creatinine, they 
will remain in the hospital until the 
methotrexate level is <0.1µM 
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